<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>药融圈 | wechat-feeds</title><link>http://MzUyNTgyNjUzMw.favicon.privacyhide.com/favicon.ico</link><description>药融圈PHARNEX汇聚数万医药大咖，得到数千家医药创业者鼎力支持，开展日常专题讲座。致力于成为“专业、前沿、权威、严谨”的医药行业资讯平台，以及项目、技术、工厂、融资、股权投资等资源整合平台。欢迎您关注药融圈，共同碰撞“药”的火花!</description><managingEditor> (hellodword)</managingEditor><pubDate>Wed, 24 Feb 2021 11:55:41 +0800</pubDate><image><url>http://MzUyNTgyNjUzMw.favicon.privacyhide.com/favicon.ico</url><title>药融圈 | wechat-feeds</title><link>http://MzUyNTgyNjUzMw.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>一文初识：日本CRO产业状况及Top 6排名</title><link>https://mp.weixin.qq.com/s/aF_Z7kt3xYbYdPqXPIbsnQ</link><description></description><content:encoded><![CDATA[一文初识：日本CRO产业状况及Top 6排名]]></content:encoded><pubDate>Wed, 24 Feb 2021 08:36:34 +0800</pubDate></item><item><title>限时免费，大湾区生物医药创新者峰会参会报名破700</title><link>https://mp.weixin.qq.com/s/0BBAAMSaB4_xuQADfKBSGQ</link><description></description><content:encoded><![CDATA[限时免费，大湾区生物医药创新者峰会参会报名破700]]></content:encoded><pubDate>Wed, 24 Feb 2021 08:36:34 +0800</pubDate></item><item><title>齐鲁、信达、君实......7款新药申请上市，73个品种过评，PD-1重磅品种新适应症获批，鼻咽癌迎来“零突破”</title><link>https://mp.weixin.qq.com/s/F1YNw6ie6I-STxMeYQ0SGg</link><description></description><content:encoded><![CDATA[齐鲁、信达、君实......7款新药申请上市，73个品种过评，PD-1重磅品种新适应症获批，鼻咽癌迎来“零突破”]]></content:encoded><pubDate>Wed, 24 Feb 2021 08:36:34 +0800</pubDate></item><item><title>重磅！礼进生物完成由IDG资本领投的数亿元人民币C轮融资</title><link>https://mp.weixin.qq.com/s/zKqGWVki1s49B1cC_DhrMA</link><description></description><content:encoded><![CDATA[重磅！礼进生物完成由IDG资本领投的数亿元人民币C轮融资]]></content:encoded><pubDate>Wed, 24 Feb 2021 08:36:34 +0800</pubDate></item><item><title>Novo Holdings宣布收购新药CRO/CDMO公司Altasciences</title><link>https://mp.weixin.qq.com/s/fq-EzKFatZ_zYpw9fhmd7Q</link><description></description><content:encoded><![CDATA[Novo Holdings宣布收购新药CRO/CDMO公司Altasciences]]></content:encoded><pubDate>Wed, 24 Feb 2021 08:36:34 +0800</pubDate></item><item><title>上药引进的PD-1抗体Prolgolimab进入III期临床</title><link>https://mp.weixin.qq.com/s/zdwDsKpy4Xp0KI2qZFj-5w</link><description></description><content:encoded><![CDATA[上药引进的PD-1抗体Prolgolimab进入III期临床]]></content:encoded><pubDate>Wed, 24 Feb 2021 08:36:34 +0800</pubDate></item><item><title>仙琚制药：醋酸泼尼松片一致性评价受理&amp;戊酸雌二醇片生产药品注册受理</title><link>https://mp.weixin.qq.com/s/r-LOBwJdTdGXH60uyCDNTg</link><description></description><content:encoded><![CDATA[仙琚制药：醋酸泼尼松片一致性评价受理&戊酸雌二醇片生产药品注册受理]]></content:encoded><pubDate>Wed, 24 Feb 2021 08:36:34 +0800</pubDate></item><item><title>医保局助力：银屑病克星IL-17苏金单抗，每支仅1198元</title><link>https://mp.weixin.qq.com/s/trkjhPKWLtd9lTnH4iDZpQ</link><description></description><content:encoded><![CDATA[医保局助力：银屑病克星IL-17苏金单抗，每支仅1198元]]></content:encoded><pubDate>Mon, 22 Feb 2021 17:07:30 +0800</pubDate></item><item><title>欧康维视低浓度阿托品滴眼液获FDA批准进入Ⅲ期临床，低浓度阿托品市场重磅玩家入局</title><link>https://mp.weixin.qq.com/s/AYFxhS6QJhRbIedAOp5R_A</link><description></description><content:encoded><![CDATA[欧康维视低浓度阿托品滴眼液获FDA批准进入Ⅲ期临床，低浓度阿托品市场重磅玩家入局]]></content:encoded><pubDate>Mon, 22 Feb 2021 17:07:30 +0800</pubDate></item><item><title>限时免费，大湾区生物医药创新者峰会参会报名破700</title><link>https://mp.weixin.qq.com/s/A7aIXI7fuMTr186rAdGOOw</link><description></description><content:encoded><![CDATA[限时免费，大湾区生物医药创新者峰会参会报名破700]]></content:encoded><pubDate>Mon, 22 Feb 2021 17:07:30 +0800</pubDate></item><item><title>来自东阳：低调API药企拟上市</title><link>https://mp.weixin.qq.com/s/LhQKUmfyGVuXS0BH3E-nBA</link><description></description><content:encoded><![CDATA[来自东阳：低调API药企拟上市]]></content:encoded><pubDate>Mon, 22 Feb 2021 17:07:30 +0800</pubDate></item><item><title>低调：绿谷创始人另一公司，景杰生物IPO在即</title><link>https://mp.weixin.qq.com/s/J3I2veIhTv4cJ1sd0Plpxg</link><description></description><content:encoded><![CDATA[低调：绿谷创始人另一公司，景杰生物IPO在即]]></content:encoded><pubDate>Mon, 22 Feb 2021 17:07:30 +0800</pubDate></item><item><title>韬略生物完成数亿元C轮融资，加速新药开发</title><link>https://mp.weixin.qq.com/s/MqyLLdu9WyzJkWUEaI_AUw</link><description></description><content:encoded><![CDATA[韬略生物完成数亿元C轮融资，加速新药开发]]></content:encoded><pubDate>Mon, 22 Feb 2021 17:07:30 +0800</pubDate></item><item><title>西湖大学副校长许田教授创立的新药公司完成5600万美元融资</title><link>https://mp.weixin.qq.com/s/Gz39CPhSk_uxxaDKbMJbKA</link><description></description><content:encoded><![CDATA[西湖大学副校长许田教授创立的新药公司完成5600万美元融资]]></content:encoded><pubDate>Mon, 22 Feb 2021 17:07:30 +0800</pubDate></item><item><title>普方生物完成千万美元融资，聚焦差异化ADC抗肿瘤新药开发</title><link>https://mp.weixin.qq.com/s/B58cP1yO0yZH6weBywz9Zw</link><description></description><content:encoded><![CDATA[普方生物完成千万美元融资，聚焦差异化ADC抗肿瘤新药开发]]></content:encoded><pubDate>Mon, 22 Feb 2021 17:07:30 +0800</pubDate></item><item><title>科创板苑东生物：以创新驱动，应对仿制药微利时代</title><link>https://mp.weixin.qq.com/s/twHsRV2UAplfXrT2YTv7CQ</link><description></description><content:encoded><![CDATA[科创板苑东生物：以创新驱动，应对仿制药微利时代]]></content:encoded><pubDate>Sun, 21 Feb 2021 21:55:37 +0800</pubDate></item><item><title>限时免费，大湾区(广州)生物医药创新者峰会参会报名破600</title><link>https://mp.weixin.qq.com/s/4txrzukYf718xu9PQyZSTA</link><description></description><content:encoded><![CDATA[限时免费，大湾区(广州)生物医药创新者峰会参会报名破600]]></content:encoded><pubDate>Sun, 21 Feb 2021 21:55:37 +0800</pubDate></item><item><title>培养基+CDMO,这家上海张江企业拟上市</title><link>https://mp.weixin.qq.com/s/xXdkUjESf5L3E0H06VbYeg</link><description></description><content:encoded><![CDATA[培养基+CDMO,这家上海张江企业拟上市]]></content:encoded><pubDate>Sun, 21 Feb 2021 21:55:37 +0800</pubDate></item><item><title>靶点药讯48|纵览全球药物靶点动态</title><link>https://mp.weixin.qq.com/s/Dn8N-ZpZRh6Nyf0EyhV9GQ</link><description></description><content:encoded><![CDATA[靶点药讯48|纵览全球药物靶点动态]]></content:encoded><pubDate>Sun, 21 Feb 2021 21:55:37 +0800</pubDate></item><item><title>胆汁酸与胆汁淤积性及相关疾病（一）原发性硬化性胆管炎（PSC）</title><link>https://mp.weixin.qq.com/s/1W8xSAAwKrzbd8P8luMP8A</link><description></description><content:encoded><![CDATA[胆汁酸与胆汁淤积性及相关疾病（一）原发性硬化性胆管炎（PSC）]]></content:encoded><pubDate>Sun, 21 Feb 2021 21:55:37 +0800</pubDate></item></channel></rss>